Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

44 results about "Anhydroicaritin" patented technology

Anhydroicaritin has stronger activity in scavenging DPPH radical than icariin,and effective inhibition against lipid peroxidation.The radical-scavenging and inhibition effects of icariin and Anhydroicaritin are dose-dependent. CONCLUSIONS: These results are useful for investigation and application of icariin and Anhydroicaritin.

Anti-ulcerative colitis pharmaceutical composition containing anhydroicaritin

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for preventing and treating ulcerative colitis as well as a preparation method and application thereof. The pharmaceutical composition disclosed by the invention comprises anhydroicaritin or a pharmaceutically acceptable salt of the anhydroicaritin and N-(3-chlorphenyl)-1-(3-hydroxybenzoyl) piperidine-4-formamide or a pharmaceutically acceptable salt of the N-(3-chlorphenyl)-1-(3-hydroxybenzoyl) piperidine-4-formamide, wherein the weight ratio of the anhydroicaritin to the N-(3-chlorphenyl)-1-(3-hydroxybenzoyl) piperidine-4-formamide is (0.1-3.0): 1. The anhydroicaritin or the pharmaceutically acceptable salt of the anhydroicaritin and the N-(3-chlorphenyl)-1-(3-hydroxybenzoyl) piperidine-4-formamide or the pharmaceutically acceptable salt of the N-(3-chlorphenyl)-1-(3-hydroxybenzoyl) piperidine-4-formamide in the pharmaceutical composition disclosed by the invention have a remarkable synergistic interaction effect in the aspect of preventing or treating ulcerative colitis. The pharmaceutical composition disclosed by the invention has a remarkable treatment effect on ulcerative colitis and has important social benefits and economic values.
Owner:LUNAN PHARMA GROUP CORPORATION